Published in J Virol on October 01, 2006
Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest (2011) 1.49
HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One (2009) 1.42
Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol (2007) 1.39
Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol (2012) 1.39
Interleukin-7 receptor signaling is deficient in CD4+ T cells from HIV-infected persons and is inversely associated with aging. J Infect Dis (2009) 1.01
Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients. Clin Exp Immunol (2014) 0.92
Effect of baseline HIV disease parameters on CD4+ T cell recovery after antiretroviral therapy initiation in Kenyan women. PLoS One (2010) 0.87
Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infection. J Acquir Immune Defic Syndr (2008) 0.81
Loss of naïve (CD45RA+) CD4+ lymphocytes during pediatric infection with feline immunodeficiency virus. Vet Immunol Immunopathol (2007) 0.78
Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropism. Sci Rep (2015) 0.77
Antiretroviral therapy suppressed participants with low CD4+ T-cell counts segregate according to opposite immunological phenotypes. AIDS (2016) 0.75
Altered phenotypic and functional characteristics of CD3+CD56+ NKT-like cells in human gastric cancer. Oncotarget (2016) 0.75
Discordant Immune Response with Antiretroviral Therapy in HIV-1: A Systematic Review of Clinical Outcomes. PLoS One (2016) 0.75
Brief Report: A High Rate of β7+ Gut-Homing Lymphocytes in HIV-Infected Immunological Nonresponders is Associated With Poor CD4 T-Cell Recovery During Suppressive HAART. J Acquir Immune Defic Syndr (2016) 0.75
A lower baseline CD4/CD8 T-cell ratio is independently associated with immunodiscordant response to antiretroviral therapy in HIV-infected subjects. Antimicrob Agents Chemother (2017) 0.75
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature (2005) 13.15
Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature (2005) 11.12
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science (1997) 10.35
Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 10.27
The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A (1997) 8.27
T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis (2003) 8.00
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol (1992) 7.92
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med (1999) 5.18
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med (2000) 4.08
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med (2000) 3.95
Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med (2000) 3.70
Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med (2002) 3.43
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med (2003) 3.41
Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest (2005) 3.08
Generation of HIV latency during thymopoiesis. Nat Med (2001) 2.91
HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation. Immunity (2004) 2.86
Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS (2001) 2.47
High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest (1998) 2.47
Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol (2001) 1.97
Multiparameter evaluation of human thymic function: interpretations and caveats. Clin Immunol (2005) 1.97
Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr (2003) 1.82
Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest (2005) 1.82
Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol (2001) 1.79
Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc Natl Acad Sci U S A (2005) 1.75
Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2005) 1.54
T cell homeostasis: thymus regeneration and peripheral T cell restoration in mice with a reduced fraction of competent precursors. J Exp Med (2001) 1.42
R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2005) 1.37
Concomitant regulation of T-cell activation and homeostasis. Nat Rev Immunol (2004) 1.29
Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methods. J Immunol Methods (1997) 1.26
CXCR4-tropic HIV-1 envelope glycoprotein functions as a viral chemokine in unstimulated primary CD4+ T lymphocytes. J Immunol (2004) 1.20
Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis (2005) 1.18
Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J Gen Virol (2005) 1.16
Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL. J Infect Dis (1998) 1.12
Glucose transporter 1 expression identifies a population of cycling CD4+ CD8+ human thymocytes with high CXCR4-induced chemotaxis. Proc Natl Acad Sci U S A (2005) 1.12
Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. J Infect Dis (2003) 1.11
De novo T-cell generation in patients at different ages and stages of HIV-1 disease. Blood (2004) 1.07
Expression and function of chemokine receptors on human thymocytes: implications for infection by human immunodeficiency virus type 1. J Virol (2001) 1.05
Dynamics of T cells and TCR excision circles differ after treatment of acute and chronic HIV infection. J Immunol (2002) 0.99
Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue. J Virol (2005) 0.99
Depletion of naive CD4 T cells by CXCR4-using HIV-1 variants occurs mainly through increased T-cell death and activation. AIDS (2003) 0.98
Involvement of Bcl-2 and IL-2R in HIV-positive patients whose CD4 cell counts fail to increase rapidly with highly active antiretroviral therapy. AIDS (2002) 0.92
Induction of simian AIDS in infant rhesus macaques infected with CCR5- or CXCR4-utilizing simian-human immunodeficiency viruses is associated with distinct lesions of the thymus. J Virol (2004) 0.84
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet (2006) 10.91
Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med (2008) 6.60
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A (2007) 4.96
Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med (2014) 4.70
Hepatitis E. Lancet (2012) 4.43
Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest (2009) 3.89
HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science (2010) 3.29
Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest (2005) 3.08
Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog (2008) 3.02
HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation. Immunity (2004) 2.86
Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis (2011) 2.75
A systematic review of computer-based patient record systems and quality of care: more randomized clinical trials or a broader approach? Int J Qual Health Care (2004) 2.31
Hepatitis E virus infection. Clin Microbiol Rev (2014) 2.21
Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol (2009) 2.17
Diversity of beta-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae. Antimicrob Agents Chemother (2002) 2.11
Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS (2008) 2.04
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology (2011) 2.01
Hepatitis E virus genotype 3 diversity, France. Emerg Infect Dis (2009) 1.99
Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol (2003) 1.96
Injection of glycosylated recombinant simian IL-7 provokes rapid and massive T-cell homing in rhesus macaques. Blood (2009) 1.89
Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol (2004) 1.85
High prevalence of anti-hepatitis E virus antibodies in blood donors from South West France. J Med Virol (2008) 1.84
Correlates of late HIV diagnosis: implications for testing policy. Int J STD AIDS (2007) 1.78
Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis (2010) 1.75
Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood (2007) 1.72
Hepatitis E virus and neurologic disorders. Emerg Infect Dis (2011) 1.70
Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology (2006) 1.64
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr (2005) 1.63
Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome. J Virol (2008) 1.62
Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood (2011) 1.62
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother (2010) 1.53
An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. Transplantation (2015) 1.52
Vienna Declaration: a call for evidence-based drug policies. Lancet (2010) 1.52
Does chronic hepatitis E virus infection exist in immunocompetent patients? Hepatology (2014) 1.49
Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest (2011) 1.49
Impact of viral factors on very early in vivo replication profiles in simian immunodeficiency virus SIVagm-infected African green monkeys. J Virol (2005) 1.48
Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant (2010) 1.48
IL-7 induces immunological improvement in SIV-infected rhesus macaques under antiviral therapy. J Immunol (2006) 1.47
Hepatitis E is an autochthonous disease in industrialized countries. Analysis of 23 patients in South-West France over a 13-month period and comparison with hepatitis A. Gastroenterol Clin Biol (2006) 1.47
Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS (2009) 1.46
Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. J Clin Microbiol (2005) 1.45
Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology (2010) 1.44
Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation (2010) 1.44
HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One (2009) 1.42
Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol (2007) 1.39
Occult hepatitis C virus infection in hemodialysis patients: examining the evidence. Am J Kidney Dis (2009) 1.39
Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS One (2012) 1.39
Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaoundé, Cameroon. J Acquir Immune Defic Syndr (2003) 1.38
R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2005) 1.37
IL-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency virus-infected macaques. J Immunol (2003) 1.37
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36
Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr (2007) 1.35
New natural intergenotypic (2/5) recombinant of hepatitis C virus. J Virol (2007) 1.34
High-Risk groups for late diagnosis of HIV infection: a need for rethinking testing policy in the general population. AIDS Patient Care STDS (2006) 1.34
CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS (2010) 1.32
p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway. Proc Natl Acad Sci U S A (2013) 1.31
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother (2005) 1.30
Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol (2009) 1.30